Skip to main
MPLT

MPLT Stock Forecast & Price Target

MPLT Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MapLight Therapeutics Inc, a clinical-stage biopharmaceutical company, has outlined a compelling perspective on its stock primarily due to the promising data surrounding its product candidate, ML-007C-MA, which targets central receptors associated with schizophrenia and Alzheimer's disease psychosis while mitigating peripheral side effects. The company reported that Cobenfy, related to its muscarinic agonist portfolio, achieved US revenues of $155 million in its first full launch year, significantly outpacing competitors and underscoring the potential for a larger total addressable market (TAM) within the muscarinic class of drugs. Additionally, improvements in safety and tolerability profiles, particularly in the context of treatment-related adverse effects and cognitive function, provide a strong foundation for MapLight Therapeutics's future growth and competitive positioning in the biopharmaceutical space.

Bears say

MapLight Therapeutics Inc. is facing significant challenges in the competitive schizophrenia market, particularly due to its delayed entry and the negative safety profile of its product candidate, ML-007C-MA, which may hinder market penetration. The lower expectations surrounding its upcoming Phase 3 readout and concerns about potential conduct issues in the clinical trials further contribute to skepticism among investors. Additionally, the company's current market capitalization of approximately $800 million is viewed as overvalued given the potential for a dramatically reduced discounted cash flow (DCF) value per share should the probability of approval decrease significantly, highlighting heightened risk associated with its financial outlook.

MPLT has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MapLight Therapeutics Inc (MPLT) Forecast

Analysts have given MPLT a Strong Buy based on their latest research and market trends.

According to 6 analysts, MPLT has a Strong Buy consensus rating as of Apr 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MapLight Therapeutics Inc (MPLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.